Core Viewpoint - Allergy Therapeutics PLC is positioned well in the allergy immunotherapy market, demonstrating stable revenue and a strong market position despite shifts in product registration in Germany [3][5]. Financial Performance - The company reported an earnings per share (EPS) of -$0.007, which matched the estimated EPS [1][5]. - Revenue for the year ending June 2025 was reported at £55 million, stable compared to the previous year, with a 2% increase when adjusted for constant exchange rates [2]. Market Dynamics - There has been a rapid shift in Germany from non-registered to fully registered allergy immunotherapy products, altering the company's product mix more swiftly than anticipated [3]. - Demand for Allergy Therapeutics' registered treatments remains strong, indicating a solid market position [3][5]. Financial Position - The company has significantly strengthened its balance sheet by repaying a £55 million shareholder loan facility and securing a new £50 million uncommitted loan facility [4][5]. - This financial flexibility is crucial as the company prepares for a key decision in 2026 [4].

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 10,666,667 shares of its common stock (or common stock equivalents in lieu thereof), Series F warrants to purchase up to 10,666,667 shares of com ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Joining us to discuss is Craig Johnson, the chief market technician at Piper Sandler and Matt Orton is the chief market strategist at Raymond James. Welcome to you both. And Craig, I think you you've said like lean into the rotation, financials, industrials, the broadening out.Is that right. >> Absolutely, Kelly. That's exactly what we're seeing in this market.And it's it's been an interesting message as I've been conveying this to investors over the last couple days. This is a bull market, but it's a rotat ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Rezolute, Inc. (NASDAQ: RZLT) experienced a significant decline in share price, falling over 85% after the failure of its Phase 3 sunRIZE study in congenital hyperinsulinism, which did not meet its primary or key secondary endpoints. This has raised concerns about potential securities law violations due to misleading statements made by the company regarding earlier data and program outlook [2][4]. Group 1: Company Performance - The share price of Rezolute, Inc. dropped more than 85% on December 11, 2025, following the announcement of the failed clinical trial results [2]. - The Phase 3 sunRIZE study aimed at treating congenital hyperinsulinism did not achieve its primary or key secondary endpoints, leading to investor losses [2]. Group 2: Legal Investigation - Block & Leviton is investigating Rezolute, Inc. for potential securities law violations and may file an action to recover losses for affected investors [4]. - Investors who purchased common stock in Rezolute, Inc. and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they sold their shares [3]. Group 3: Investor Support - Block & Leviton encourages investors who have lost money to contact them for assistance in recovering losses [5]. - The firm is recognized as a leading securities class action firm, having recovered billions for defrauded investors through litigation [7].

MLTX DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action - MLTXDecember 12, 2025 2:12 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - December 12, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 202 ...

First Patient Expected to be Dosed Next Week with Intranasal ForalumabPET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi® (Lecanemab) Anti-Amyloid Therapy BOSTON, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that enrolment ...

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) stock is trading lower on Friday, with a session volume of 42.39 million compared to the average volume of 3.51 million as per data from Benzinga Pro. • Tenaya Therapeutics stock is feeling bearish pressure. What’s pressuring TNYA stock?On Thursday, Tenaya Therapeutics priced its underwritten public offering of 50 million units at $1.20 per unit for gross proceeds of $60 million. Each unit consists of one share and a warrant to purchase one share of common stock at an ...